Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study of early HCV viral load decline with ombitasvir/ABT-450/ritonavir and dasabuvir plus varying ribavirin dosing in treatment-naive genotype 1a adults
2014-001478-32Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in chronic hepatitis C (CHC) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Slope of second-phase decline in plasma HCV RNA levels. Started Jun 2015; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirdasabuvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2014-001478-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001478-32.